Press Releases from AFFiRiS AG (8 total)
AFFiRiS AG successfully raises €10m equity financing
• € 10m additional capital raised
• Strengthened management team, Günther Staffler appointed as Chief Technology Officer
• Noel Barrett appointed as additional member of the supervisory…
Vaccine Development Boosted With 10 Mio. Euros at AFFiRiS AG
Vaccine Specialist AFFiRiS AG successfully completes Financing Round
• € 10m additional capital raised
• Supervisory Board appoints Oliver Siegel as Chief Executive Officer
• Prof. Dr. Christoph Huber elected to…
New board member joins AFFiRiS AG
Vienna, 9. September 2014 – AFFiRiS AG today announced the appointment of Oliver Siegel as a new member of the Executive Management Board. He will…
AFFiRiS AG: ALZHEIMER'S VACCINE AD02 ALREADY IN CLINICAL PHASE II
Vienna (Austria), 23. April 2010: AFFiRiS AG's clinical Alzheimer's vaccine candidate AD02 has already progressed to phase II clinical testing. It may therefore be possible…
Alzheimer's Vaccine Candidate AD02 into Clinical Phase II Testing
AFFiRiS AG: Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimer's Vaccine Candidate AD02 into Clinical Phase II Testing
Vienna, November 18, 2009:…
AFFiRiS AG - ENCOURAGING RESULTS FROM PHASE I STUDIES OF TWO ALZHEIMER'S CANDIDA …
Vienna, 20. October 2009: AFFiRiS AG today announced that the primary endpoints have been met for the Phase I clinical studies of its two Alzheimer's…
AFFiRiS AG: 1st Place in Venture Capital & Private Equity Awards for MIG Fonds a …
Vienna, 23rd June 2009. MIG Fonds and AFFiRiS AG are this year's winners of the 2009 Venture Capital & Private Equity award competition hosted by…
Affiris Expands Patent Portfolio for Alzheimer’s Therapies
Vienna, 27. February 2008. Affiris GmbH has secured another Europe-wide patent for an innovative method of treating Alzheimer\'s disease. This new blood-cleansing method is similar…
Go To Page:
